A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
about
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisUK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST).Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.Tumor volume as an alternative response measurement for imatinib treated GIST patients.Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Update on imatinib for gastrointestinal stromal tumors: duration of treatment.Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour.Cancer pharmacogenomics: early promise, but concerted effort needed.Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib ExposureClinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Controversies in the management of gastrointestinal stromal tumors.Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingDevelopment of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients.Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Pharmacology and pharmacokinetics of imatinib in pediatric patients.Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia
P2860
Q26800005-C21D63B5-F0A3-4AB4-BB57-5715548025E9Q33612778-CB9F3DD5-B9EA-4F67-BAEE-B6B30EABD82EQ33613666-448E946C-7392-4C07-A1B0-B3E347338C1DQ34469701-866B6962-D3CA-48F3-A6C1-AAE5CDA9FDCEQ35909678-792B548A-8C97-4A9A-B2C5-E71DBD8F2AEAQ36243653-B250DBFA-27DB-47E8-99EE-161B9F37CEBAQ37075052-4A04EE57-AE32-4180-81BA-294BF20F8375Q37367438-D6D5BE43-2065-4267-8D47-A946B99A3C67Q37504935-7B6B86F5-0748-443D-A454-14AAD97F293CQ37508335-3BACFB8D-52A2-4498-AE88-A0F080DE670BQ37650706-485D79A0-1BE5-4157-9DD0-6120C67F7A26Q38112821-00336B8C-538E-4C25-A103-21008758D920Q38190857-146B83C7-7645-4B2F-A3ED-91E48C412D83Q38199797-077E997E-06B6-4FAF-AF25-6676E70D0307Q38852974-C799B515-36A6-43C7-AE98-3D90A604D15DQ38968504-13E63BC5-D3ED-4BEB-B703-DFD124556833Q39480956-3551C7D2-3ED5-406B-814B-D11470608A87Q44529953-FCE84174-956E-46EA-B29A-A0A8E8474E13Q45228150-8A19019E-DBF8-47EE-A9C5-D2155603F60AQ45403481-243D615B-1349-478F-B987-DF828F110413Q46431899-AA2B975C-D4F3-4FED-987F-28FFB1916BC5Q47637910-17712578-F94A-4569-BFA9-5975A424AC77Q47847397-FE0B3109-A0C2-4C84-B3EC-0BCCFA866B2AQ47969048-C29BC2B8-97DF-4201-9BFF-E5C7500CC347Q48152547-6D317E52-AEE8-4CA1-A081-2FDC16FC5AEAQ48248167-0BC455F7-31A8-4684-A2AC-CE7ECFE371F4Q48826707-DE92FEF9-E9E4-4669-9090-C012F5144D17Q50091855-933E1408-FD1A-4ACD-8595-9B0B47D538D1Q50094239-3DC92D27-50B9-47B6-82CD-7E6B5AE60CD4Q50193732-D4E484AF-6F6E-4145-8B4F-EF20F0500FEDQ55070104-E8D38ED3-5FF7-4C7B-A359-393356C44DD4Q56973578-DAB81DD8-FD26-4857-A983-00BA7B05CC6B
P2860
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A long-term prospective popula ...... ncentrations in GIST patients.
@ast
A long-term prospective popula ...... ncentrations in GIST patients.
@en
A long-term prospective popula ...... ncentrations in GIST patients.
@nl
type
label
A long-term prospective popula ...... ncentrations in GIST patients.
@ast
A long-term prospective popula ...... ncentrations in GIST patients.
@en
A long-term prospective popula ...... ncentrations in GIST patients.
@nl
prefLabel
A long-term prospective popula ...... ncentrations in GIST patients.
@ast
A long-term prospective popula ...... ncentrations in GIST patients.
@en
A long-term prospective popula ...... ncentrations in GIST patients.
@nl
P2093
P1476
A long-term prospective popula ...... ncentrations in GIST patients.
@en
P2093
An K Reyners
Erik A C Wiemer
Floris A de Jong
Gaia Schiavon
Jaap Verweij
Karel Eechoute
Lena E Friberg
Martin N Fransson
Ron H J Mathijssen
Ugo De Giorgi
P304
P356
10.1158/1078-0432.CCR-12-0490
P407
P577
2012-07-31T00:00:00Z